skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

Law, M R ; Wald, N J ; Rudnicka, A R

BMJ, 2003-06, Vol.326 (7404), p.1423-1427 [Periódico revisado por pares]

London: British Medical Journal Publishing Group

Texto completo disponível

Citações Citado por
  • Título:
    Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
  • Autor: Law, M R ; Wald, N J ; Rudnicka, A R
  • Assuntos: Biological and medical sciences ; Cholesterol, LDL - blood ; Cholesterols ; Cohort Studies ; Dosage ; Double-Blind Method ; Experimentation ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Medical sciences ; Myocardial ischemia ; Myocardial Ischemia - prevention & control ; Pharmacology. Drug treatments ; Placebos ; Pretreatment ; Randomized Controlled Trials as Topic ; Risk Factors ; Serum cholesterol ; Stroke - prevention & control ; Strokes ; Vascular diseases
  • É parte de: BMJ, 2003-06, Vol.326 (7404), p.1423-1427
  • Notas: Correspondence to: M R Law
    ArticleID:bmj.326.7404.1423
    local:bmj;326/7404/1423
    istex:9A1C1AA790F80FA62C650A73913322871F789FCA
    ark:/67375/NVC-KQJ1ZJ04-L
    PMID:12829554
    href:bmj-326-1423.pdf
    ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-1
    ObjectType-Review-4
    content type line 23
    ObjectType-Undefined-3
    Contributors: MRL, NJW, and ARR wrote the paper. MRL and ARR abstracted the data. ARR carried out the statistical analyses. All authors interpreted the results. MRL is guarantor.
    Competing interests: NW and ML have filed a patent application on the formula of a combined pill to simultaneously reduce four cardiovascular risk factors.
    We thank the following authors for unpublished data from trials: V Athyros (GREACE), M Bortolini and P Serruys (LIPS), A Tonkin and A Kirby (LIPID), T Pedersen and T Cook (4S), and G Steiner (DAIS), as well as the authors acknowledged in our earlier paper. We also thank Leo Kinlen for his comments on the manuscript.
    Funding: ARR was supported by an NHS research and development programme award. The guarantor accepts full responsibility for the conduct of the study, had access to the data, and controlled the decision to publish.
    Correspondence to: M R Law m.r.law@qmul.ac.uk
    A full list of references and two extra tables can be found on bmj.com
  • Descrição: Abstract Objectives To determine by how much statins reduce serum concentrations of low density lipoprotein (LDL) cholesterol and incidence of ischaemic heart disease (IHD) events and stroke, according to drug, dose, and duration of treatment. Design Three meta-analyses: 164 short term randomised placebo controlled trials of six statins and LDL cholesterol reduction; 58 randomised trials of cholesterol lowering by any means and IHD events; and nine cohort studies and the same 58 trials on stoke. Main outcome measures Reductions in LDL cholesterol according to statin and dose; reduction in IHD events and stroke for a specified reduction in LDL cholesterol. Results Reductions in LDL cholesterol (in the 164 trials) were 2.8 mmol/l (60%) with rosuvastatin 80 mg/day, 2.6 mmol/l (55%) with atorvastatin 80 mg/day, 1.8 mmol/l (40%) with atorvastatin 10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day, or rosuvastatin 5 mg/day, all from pretreatment concentrations of 4.8 mmol/l. Pravastatin and fluvastatin achieved smaller reductions. In the 58 trials, for an LDL cholesterol reduction of 1.0 mmol/l the risk of IHD events was reduced by 11% in the first year of treatment, 24% in the second year, 33% in years three to five, and by 36% thereafter (P < 0.001 for trend). IHD events were reduced by 20%, 31%, and 51% in trials grouped by LDL cholesterol reduction (means 0.5 mmol/l, 1.0 mmol/l, and 1.6 mmol/l) after results from first two years of treatment were excluded (P < 0.001 for trend). After several years a reduction of 1.8 mmol/l would reduce IHD events by an estimated 61%. Results from the same 58 trials, corroborated by results from the nine cohort studies, show that lowering LDL cholesterol decreases all stroke by 10% for a 1 mmol/l reduction and 17% for a 1.8 mmol/l reduction. Estimates allow for the fact that trials tended to recruit people with vascular disease, among whom the effect of LDL cholesterol reduction on stroke is greater because of their higher risk of thromboembolic stroke (rather than haemorrhagic stroke) compared with people in the general population. Conclusions Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17%.
  • Editor: London: British Medical Journal Publishing Group
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.